CytomX Therapeutics (CTMX) Receives $40.17 Average PT from Brokerages

Shares of CytomX Therapeutics (NASDAQ:CTMX) have earned an average rating of “Buy” from the thirteen analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $40.17.

A number of research firms recently weighed in on CTMX. Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, February 5th. Cantor Fitzgerald set a $40.00 target price on shares of CytomX Therapeutics and gave the stock a “buy” rating in a research note on Saturday, March 17th. BidaskClub lowered shares of CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 30th. Citigroup began coverage on shares of CytomX Therapeutics in a research note on Friday, January 5th. They set a “buy” rating and a $40.00 target price on the stock. Finally, ValuEngine upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd.

How to Become a New Pot Stock Millionaire

Shares of CTMX stock traded down $0.01 during trading hours on Thursday, reaching $27.28. 87,293 shares of the stock were exchanged, compared to its average volume of 366,013. CytomX Therapeutics has a 12-month low of $13.00 and a 12-month high of $35.00. The firm has a market capitalization of $1,104.67, a price-to-earnings ratio of -23.45 and a beta of 0.91.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.45. CytomX Therapeutics had a negative net margin of 60.17% and a negative return on equity of 71.42%. The firm had revenue of $27.07 million for the quarter, compared to analyst estimates of $10.70 million. sell-side analysts forecast that CytomX Therapeutics will post -1.44 earnings per share for the current fiscal year.

In related news, Director Frederick W. Gluck sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 26th. The stock was sold at an average price of $31.93, for a total value of $159,650.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Debanjan Ray sold 2,548 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $26.69, for a total value of $68,006.12. Following the completion of the transaction, the chief financial officer now directly owns 4,741 shares of the company’s stock, valued at $126,537.29. The disclosure for this sale can be found here. Insiders sold 103,548 shares of company stock valued at $3,101,686 over the last ninety days. 8.00% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. AMP Capital Investors Ltd boosted its holdings in shares of CytomX Therapeutics by 64.7% in the fourth quarter. AMP Capital Investors Ltd now owns 66,621 shares of the biotechnology company’s stock valued at $1,406,000 after acquiring an additional 26,183 shares during the period. Renaissance Technologies LLC raised its position in CytomX Therapeutics by 32.9% in the fourth quarter. Renaissance Technologies LLC now owns 715,100 shares of the biotechnology company’s stock worth $15,096,000 after acquiring an additional 177,200 shares in the last quarter. Hamilton Lane Advisors LLC raised its position in CytomX Therapeutics by 77.8% in the fourth quarter. Hamilton Lane Advisors LLC now owns 50,394 shares of the biotechnology company’s stock worth $1,064,000 after acquiring an additional 22,048 shares in the last quarter. Redmile Group LLC raised its position in CytomX Therapeutics by 9.5% in the fourth quarter. Redmile Group LLC now owns 418,680 shares of the biotechnology company’s stock worth $8,838,000 after acquiring an additional 36,409 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in CytomX Therapeutics by 12.0% in the fourth quarter. Two Sigma Investments LP now owns 153,340 shares of the biotechnology company’s stock worth $3,237,000 after acquiring an additional 16,479 shares in the last quarter. 78.07% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/17/cytomx-therapeutics-ctmx-receives-40-17-average-pt-from-brokerages.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply